Abstract:Associations between amyloid and downstream measures of Alzheimer disease (AD) are often lacking. In autosomal dominant AD (ADAD), cerebrospinal fluid (CSF) phosphorylated tau 217 and 181 (pT217 and pT181) increase shortly after amyloid positron emission tomography (PET), followed by tau 205 (pT205), then tau PET. Each site also tracks closely with disease progression and is associated with longitudinal cognitive decline. Collectively these findings lead to the question of which p‐tau sites affect the relationship between amyloid and downstream AD markers (i.e., tau, MRI cortical thickness, Clinical Dementia Rating [CDR] Scale status), and more specifically whether they mediate such associations. CSF tau phosphorylation occupancy on 217, 181 and 205 residues, CSF total tau (t‐tau), amyloid PET, ADAD cortical thickness signature, and CDR status were measured in 150 individuals from the Dominantly Inherited Alzheimer Network (non‐mutation carrier [MC‐]; n=64; and mutation carrier [MC+]; n=86). Three multiple mediation analyses assuming nonlinear relationships were performed with amyloid PET as the predictor variable, CSF p‐tau sites (pT217, pT181, pT205) and t‐tau (when appropriate) as mediators, and either CSF t‐tau, cortical thickness, or CDR status as the outcome variables. For each model, estimated years to symptom onset (EYO), age, sex, and ADAD mutation status were included as covariates. All models were run with 500 iterations to bootstrap confidence intervals. Increased amyloid PET was associated with elevated CSF pT217, pT181, and pT205 (p’s<0.03). For each model, the effects of amyloid PET on downstream AD markers were jointly mediated by CSF pT217 and pT205. Specifically, elevated CSF pT217 and pT205 were associated with increased CSF t‐tau, decreased cortical thickness, and higher CDR scores (p’s<0.01). CSF t‐tau and pT181 did not mediate these relationships (p’s>0.05). Elevated pT217 and pT205, but not pT181 or t‐tau, mediate the relationship between amyloid and downstream AD biomarkers in ADAD. AD‐related brain atrophy and clinical status may be dependent on specific tau sites; future mechanistic experiments are needed to fully understand such relationships. These results support the hypothesis that tau phosphorylation at specific sites plays a critical role in the progression and pathogenesis of ADAD, and may be a possible target for future treatments.

p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation.

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

CDK5 Participates in Amyloid-β Production by Regulating PPARγ Phosphorylation in Primary Rat Hippocampal Neurons.

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

Protein Kinase C-Delta Mediates Cell Cycle Reentry and Apoptosis Induced by Amyloid-Beta Peptide in Post-Mitotic Cortical Neurons

Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

The Effect Ofcdk-5 Overexpression and Overactivation on Tau Hyperphosphorylation in Cultured N2a Cells

[P4–126]: Δ‐secretase–cleaved TAU STIMULATES Aβ PRODUCTION VIA ACTIVATING STAT1‐BACE1 PATHWAY IN ALZHEIMER's DISEASE

Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology

Calcium Ions Stimulate the Hyperphosphorylation of Tau by Activating Microsomal Prostaglandin E Synthase 1

PI3K/AKT/mTOR/p70S6K Pathway Is Involved in Aβ25-35-Induced Autophagy.

Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins.

Changes in the prefrontal cortex after the hippocampus was injected with Aβ25-35 via the P35/P25-CDK5-Tau hyperphosphorylation signaling pathway

CSF tau phosphorylation at sites 217 and 205 mediate the relationship between PET amyloid and downstream AD markers

Cyclin-Dependent Kinase 5--A Neuronal Killer?

Hyperphosphorylation of Tau Protein by Calpain Regulation in Retina of Alzheimer's Disease Transgenic Mouse